In 2009 Novartis and MMV launched the first high-quality artemisinin combination therapy (ACT) formulated especially for children – Coartem®Dispersible (artemether-lumefantrine). Since then, 400 million treatments of this life-saving medicine have been delivered to over 50 malaria-endemic countries.
MMV is dedicated to developing new medicines for vulnerable populations: children and pregnant women, who are at greatest risk of dying from malaria.
Developing better medicines for children
MMV has long recognized that developing better medicines for children helps address the most vulnerable patient population at greatest risk of dying from malaria.